Overview

* Seres Therapeutics ( MCRB ) reports Q3 net income of $8.2 mln, reversing a loss from last year

* Company reduces operating expenses through cost-reduction measures, including workforce reductions

* Seres finalizing SER-155 Phase 2 study protocol, interim results expected within 12 months

* Seres receives $3.6 mln CARB-X grant for SER-155 development

Outlook

* Seres expects interim results from SER-155 Phase 2 study within 12 months of initiation

* Company anticipates initial results from immune checkpoint enterocolitis study in early 2026

* Seres expects to fund operations through Q2 2026

Result Drivers

* COST REDUCTION - Seres implemented cost-reduction measures, including workforce reductions, to fund operations through Q2 2026

* CARB-X GRANT - Seres received a $3.6 mln grant from CARB-X to support the development of an oral liquid formulation of SER-155

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $351,000

Collabor

ation

Revenue

Q3 EPS $0.94

Q3 Net $8.20

Income mln

Q3 $22.82

Operatin mln

g

Expenses

Q3 -$22.47

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Seres Therapeutics Inc ( MCRB ) is $20.00, about 31.3% above its November 4 closing price of $13.75

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)